Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Cyteir Therapeutics Inc.
Headquarters: Lexington, MA, United States of America
Website: N/A
Year Founded: 2012
Status: Out of Business
BioCentury | Feb 25, 2025
Management Tracks
After leaving FDA, Cavazzoni joins Pfizer as CMO
Plus: CFO hires at Nuclera, Crinetics, Terns and updates from Xeris, Inhibikase and Climb Bio
BioCentury | Jul 16, 2024
Management Tracks
More moves at the top for I-Mab
Plus: Daniel Janse named CEO at AffyImmune, and updates from HanAll, Mogrify, Rectify and Atsena
BioCentury | May 23, 2023
Management Tracks
Coelho succeeds Lankry as Gamida CFO
Plus: Sullivan becomes chief strategy officer at BioAge, and updates from Athira, Ambrx and FNIH
BioCentury | Jun 18, 2021
Finance
Aftermarket performance by Verve strongest among seven biotechs listing this week
Although signs have emerged that investor demand for new biotech listings has cooled somewhat from a fever pitch early in the year, the seven IPOs priced between Wednesday night and Friday morning
BioCentury | Apr 21, 2021
Product Development
Synthetic lethality’s second wind
The thinking goes beyond the binary paradigm of target plus mutation
BioCentury | Feb 12, 2021
Finance
Public listing, Phase II cancer readouts in Cyteir’s sights as it banks $80M crossover round
With early efficacy signals emerging from a dose-finding study, Cyteir will use its new $80 million series C crossover round to gain Phase II data in multiple cancers for its DNA damage repair (DDR)
BioCentury | Oct 15, 2019
Finance
Cyteir synthetic lethality compound prompts Novo to lead $40M investment
Cyteir is Novo Holdings’ first investment in the DNA damage repair space
BioCentury | Nov 30, 2018
Targets & Mechanisms
Revving up metabolism at ASH 2018
A dive into the ASH 2018 abstracts highlights cancer metabolism as a top focus
Items per page:
1 - 10 of 16